



## **Amal Therapeutics SA announces the appointment of Dr. Jean-Yves Bonnefoy as member of the Scientific Advisory Board**

**Geneva, Switzerland, April 8, 2016** – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced the appointment of Jean-Yves Bonnefoy as new Scientific Advisory Board (SAB) member. Dr. Bonnefoy will bring over 20 years experience in Biotechnology company leadership and therapeutic cancer vaccine development.

Dr. Bonnefoy worked for several biotech and pharmaceutical companies in managerial position. Presently CEO of Anagenesis Biotechnologies, he namely held the position of VP R&D of Transgene SA during 9 years, launched and managed the Cancéropôle Lyon Rhône-Alpes and was before Director of the Pierre Fabre Immunology Center. Jean-Yves Bonnefoy holds a PhD in Immunology and is author and co-author of more than 230 publications and reviews.

Dr. Derouazi, CEO of Amal Therapeutics, says: *“I am delighted that Dr. Bonnefoy accepted to join our SAB. His knowledge and experience in therapeutic cancer vaccines and tumor immunology will certainly be an important contribution to Amal Therapeutics development in the coming years.”*

### **About Amal Therapeutics**

Amal Therapeutics SA is a privately held Swiss biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses KISIMA, its proprietary vaccine technology platform to develop and progress therapeutic vaccines in oncology. [www.amaltherapeutics.com](http://www.amaltherapeutics.com), [contact@amaltherapeutics.com](mailto:contact@amaltherapeutics.com)